{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:07:56Z","timestamp":1793912876825,"version":"4.8.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.mehy.2020.110005","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T21:43:23Z","timestamp":1592343803000},"page":"110005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Pirfenidone: A novel hypothetical treatment for COVID-19"],"prefix":"10.1016","volume":"144","author":[{"given":"Soroush","family":"Seifirad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.110005_b0005","unstructured":"Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls. Treasure Island (FL)2020."},{"key":"10.1016\/j.mehy.2020.110005_b0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jgar.2020.02.021","article-title":"2019 novel coronavirus (2019-nCoV) outbreak: a new challenge","volume":"21","author":"Lupia","year":"2020","journal-title":"J Global Antimicrob Resist"},{"key":"10.1016\/j.mehy.2020.110005_b0015","doi-asserted-by":"crossref","unstructured":"Huang G, Gong T, Wang G, Wang J, Guo X, Cai E, et al. Timely Diagnosis and Treatment Shortens the Time to Resolution of Coronavirus Disease (COVID-19) Pneumonia and Lowers the Highest and Last CT Scores From Sequential Chest CT. AJR American journal of roentgenology. 2020:1-7.","DOI":"10.2214\/AJR.20.23078"},{"key":"10.1016\/j.mehy.2020.110005_b0020","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents. 2020:105949.","DOI":"10.1101\/2020.03.16.20037135"},{"key":"10.1016\/j.mehy.2020.110005_b0025","doi-asserted-by":"crossref","unstructured":"Schlagenhauf P, Grobusch MP, Maier JD, Gautret P. Repurposing antimalarials and other drugs for COVID-19. Travel medicine and infectious disease. 2020:101658.","DOI":"10.1016\/j.tmaid.2020.101658"},{"key":"10.1016\/j.mehy.2020.110005_b0030","doi-asserted-by":"crossref","unstructured":"Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Revista panamericana de salud publica = Pan American journal of public health. 2020;44:e40.","DOI":"10.26633\/RPSP.2020.40"},{"key":"10.1016\/j.mehy.2020.110005_b0035","article-title":"Compassionate Use of Remdesivir in Covid-19","volume":"382","author":"Bonovas","year":"2020","journal-title":"N England J Med"},{"key":"10.1016\/j.mehy.2020.110005_b0040","doi-asserted-by":"crossref","unstructured":"Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel medicine and infectious disease. 2020;34:101615.","DOI":"10.1016\/j.tmaid.2020.101615"},{"key":"10.1016\/j.mehy.2020.110005_b0045","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. The New England journal of medicine. 2020."},{"key":"10.1016\/j.mehy.2020.110005_b0050","doi-asserted-by":"crossref","unstructured":"Davies M, Osborne V, Lane S, Roy D, Dhanda S, Evans A, et al. Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. Drug safety. 2020.","DOI":"10.1101\/2020.05.07.20093898"},{"issue":"8","key":"10.1016\/j.mehy.2020.110005_b0055","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3109\/15563650.2012.718783","article-title":"Effect of pirfenidone on pulmonary fibrosis due to paraquat poisoning in rats","volume":"50","author":"Seifirad","year":"2012","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.mehy.2020.110005_b0060","doi-asserted-by":"crossref","unstructured":"Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, et al. Longitudinal \u201cReal-World\u201d Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece. Frontiers in medicine. 2017;4:213.","DOI":"10.3389\/fmed.2017.00213"},{"issue":"5","key":"10.1016\/j.mehy.2020.110005_b0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/bdd.311","article-title":"Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration","volume":"23","author":"Giri","year":"2002","journal-title":"Biopharm. Drug Dispos."},{"issue":"4","key":"10.1016\/j.mehy.2020.110005_b0070","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.mehy.2020.110005_b0075","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.mehy.2020.110005_b0080","doi-asserted-by":"crossref","unstructured":"Lin X, Yu M, Wu K, Yuan H, Zhong H. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro. Investigative ophthalmology & visual science. 2009;50(8):3763-70.","DOI":"10.1167\/iovs.08-2815"},{"issue":"2","key":"10.1016\/j.mehy.2020.110005_b0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1034\/j.1600-6143.2002.020201.x","article-title":"Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity","volume":"2","author":"Shihab","year":"2002","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.mehy.2020.110005_b0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/toxsci\/kfg167","article-title":"Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity","volume":"75","author":"Card","year":"2003","journal-title":"Toxicol Sci"},{"issue":"5","key":"10.1016\/j.mehy.2020.110005_b0095","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.intimp.2008.01.013","article-title":"Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro","volume":"8","author":"Grattendick","year":"2008","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"10.1016\/j.mehy.2020.110005_b0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0192-0561(98)00042-3","article-title":"Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone","volume":"20","author":"Cain","year":"1998","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.mehy.2020.110005_b0105","article-title":"Pirfenidone controls the feedback loop of the AT1R\/p38 MAPK\/renin-angiotensin system axis by regulating liver X receptor-alpha in myocardial infarction-induced cardiac fibrosis","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.mehy.2020.110005_b0110","doi-asserted-by":"crossref","unstructured":"Fois AG, Posadino AM, Giordo R, Cossu A, Agouni A, Rizk NM, et al. Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients. Oxidative medicine and cellular longevity. 2018;2018:2639081.","DOI":"10.1155\/2018\/2639081"},{"issue":"3","key":"10.1016\/j.mehy.2020.110005_b0115","first-page":"169","article-title":"Effects of pirfenidone on the generation of reactive oxygen species in vitro","volume":"18","author":"Giri","year":"1999","journal-title":"J Environ Pathol Toxicol Oncology"},{"key":"10.1016\/j.mehy.2020.110005_b0120","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","volume":"105954","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mehy.2020.110005_b0125","doi-asserted-by":"crossref","unstructured":"Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2020.","DOI":"10.1016\/j.jmii.2020.03.005"},{"key":"10.1016\/j.mehy.2020.110005_b0130","unstructured":"Gou FX, Zhang XS, Yao JX, Yu DS, Wei KF, Zhang H, et al. [Epidemiological characteristics of COVID-19 in Gansu province]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2020;41(0):E032."},{"key":"10.1016\/j.mehy.2020.110005_b0135","doi-asserted-by":"crossref","unstructured":"Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious diseases of poverty. 2020;9(1):29.","DOI":"10.1186\/s40249-020-00646-x"},{"key":"10.1016\/j.mehy.2020.110005_b0140","article-title":"A 55-Day-Old Female Infant infected with COVID 19: presenting with pneumonia, liver injury, and heart damage","author":"Cui","year":"2020","journal-title":"J Infect Dis"},{"issue":"10228","key":"10.1016\/j.mehy.2020.110005_b0145","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S0140-6736(20)30558-4","article-title":"Comorbidities and multi-organ injuries in the treatment of COVID-19","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mehy.2020.110005_b0150","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1378\/chest.11-2879","article-title":"Effects of lecithinized superoxide dismutase and\/or pirfenidone against bleomycin-induced pulmonary fibrosis","volume":"142","author":"Tanaka","year":"2012","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.mehy.2020.110005_b0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2220\/biomedres.34.309","article-title":"Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways","volume":"34","author":"Ji","year":"2013","journal-title":"Biomed. Res."},{"issue":"8","key":"10.1016\/j.mehy.2020.110005_b0160","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2460\/ajvr.70.8.1031","article-title":"Effects of intravenous administration of pirfenidone on horses with experimentally induced endotoxemia","volume":"70","author":"Poulin Braim","year":"2009","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.mehy.2020.110005_b0165","doi-asserted-by":"crossref","unstructured":"Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y, et al. In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PloS one. 2011;6(11):e28134.","DOI":"10.1371\/journal.pone.0028134"},{"issue":"6","key":"10.1016\/j.mehy.2020.110005_b0170","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/IAI.70.6.2989-2994.2002","article-title":"Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B","volume":"70","author":"Hale","year":"2002","journal-title":"IAI"},{"key":"10.1016\/j.mehy.2020.110005_b0175","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.molimm.2018.05.003","article-title":"Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation","volume":"99","author":"Li","year":"2018","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110005_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000351179","article-title":"Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing nlrp3 inflammasome formation","volume":"126","author":"Wang","year":"2013","journal-title":"Cardiology"},{"key":"10.1016\/j.mehy.2020.110005_b0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","article-title":"Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts","volume":"58","author":"Conte","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.mehy.2020.110005_b0190","doi-asserted-by":"crossref","unstructured":"Yang Y, Ye Y, Lin X, Wu K, Yu M. Inhibition of pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transition of human lens epithelial cells line SRA01\/04. PloS one. 2013;8(2):e56837.","DOI":"10.1371\/journal.pone.0056837"},{"key":"10.1016\/j.mehy.2020.110005_b0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bcp.2016.08.002","article-title":"Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-beta signaling in a murine colitis model","volume":"117","author":"Li","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110005_b0200","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-3565(24)35110-9","article-title":"Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"291","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Therap."},{"issue":"1","key":"10.1016\/j.mehy.2020.110005_b0205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1165\/rcmb.2016-0217OC","article-title":"A novel antifibrotic mechanism of nintedanib and pirfenidone. inhibition of collagen fibril assembly","volume":"57","author":"Kn\u00fcppel","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110005_b0210","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3565(24)38125-X","article-title":"Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"289","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Therap"},{"key":"10.1016\/j.mehy.2020.110005_b0215","doi-asserted-by":"crossref","unstructured":"Tzouvelekis A, Wolters PJ. Pirfenidone in the kaleidoscope: reflecting mechanisms through different angles. The European respiratory journal. 2018;52(5).","DOI":"10.1183\/13993003.02046-2018"},{"key":"10.1016\/j.mehy.2020.110005_b0220","doi-asserted-by":"crossref","unstructured":"Xie Y, Jiang H, Zhang Q, Mehrotra S, Abel PW, Toews ML, et al. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis. Respiratory research. 2016;17(1):103.","DOI":"10.1186\/s12931-016-0418-4"},{"issue":"1\u20132","key":"10.1016\/j.mehy.2020.110005_b0225","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1007023532508","article-title":"Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals","volume":"204","author":"Misra","year":"2000","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"10.1016\/j.mehy.2020.110005_b0230","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00280-003-0703-z","article-title":"Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats","volume":"53","author":"Du","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.mehy.2020.110005_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/281613","article-title":"Fas\/FasL Pathway Participates in regulation of antiviral and inflammatory response during mousepox infection of lungs","volume":"2015","author":"Bie\u0144","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"4","key":"10.1016\/j.mehy.2020.110005_b0240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.TP.0000151721.99418.48","article-title":"Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity","volume":"79","author":"Shihab","year":"2005","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.mehy.2020.110005_b0245","first-page":"1081","article-title":"Pirfenidone attenuates homocysteineinduced apoptosis by regulating the connexin 43 pathway in H9C2 cells","volume":"45","author":"Chen","year":"2020","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.mehy.2020.110005_b0250","first-page":"2626","article-title":"Pirfenidone inhibits migration, differentiation, and proliferation of human retinal pigment epithelial cells in vitro","volume":"19","author":"Wang","year":"2013","journal-title":"Mol Vision"},{"issue":"1","key":"10.1016\/j.mehy.2020.110005_b0255","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","article-title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients","volume":"9","author":"Xiong","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.mehy.2020.110005_b0260","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25804","article-title":"CD-sACE2 Inclusion Compounds: an effective treatment for corona virus disease 2019 (COVID-19)","author":"Sun","year":"2020","journal-title":"J Med Virol"},{"issue":"10229","key":"10.1016\/j.mehy.2020.110005_b0265","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.mehy.2020.110005_b0270","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID\u201019: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"issue":"5","key":"10.1016\/j.mehy.2020.110005_b0275","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.resinv.2015.06.001","article-title":"All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis","volume":"53","author":"Ogura","year":"2015","journal-title":"Respir Investig"},{"issue":"5","key":"10.1016\/j.mehy.2020.110005_b0280","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2169\/internalmedicine.55.5272","article-title":"Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis","volume":"55","author":"Bando","year":"2016","journal-title":"Intern. Med."},{"issue":"6","key":"10.1016\/j.mehy.2020.110005_b0285","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.resinv.2015.06.002","article-title":"Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan","volume":"53","author":"Taguchi","year":"2015","journal-title":"Respir Investig"},{"key":"10.1016\/j.mehy.2020.110005_b0290","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pupt.2017.08.011","article-title":"Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis: a real-world observational study","volume":"46","author":"Tzouvelekis","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.mehy.2020.110005_b0295","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s10753-017-0671-9","article-title":"Combination therapy with pirfenidone plus prednisolone ameliorates paraquat-induced pulmonary fibrosis","volume":"41","author":"Rasooli","year":"2018","journal-title":"Inflammation"},{"key":"10.1016\/j.mehy.2020.110005_b0300","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.fct.2017.12.034","article-title":"Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression","volume":"112","author":"Pourgholamhossein","year":"2018","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.mehy.2020.110005_b0305","doi-asserted-by":"crossref","unstructured":"Blanco-Ayala T, Anderica-Romero AC, Pedraza-Chaverri J. New insights into antioxidant strategies against paraquat toxicity. Free radical research. 2014;48(6):623-40.","DOI":"10.3109\/10715762.2014.899694"},{"key":"10.1016\/j.mehy.2020.110005_b0310","doi-asserted-by":"crossref","unstructured":"Seifirad S. Pirfenidone could decrease paraquat-induced pulmonary fibrosis in rats. Tzu Chi Medical Journal. 2013;25(2):130.","DOI":"10.1016\/j.tcmj.2013.03.002"},{"issue":"1","key":"10.1016\/j.mehy.2020.110005_b0315","first-page":"85","article-title":"Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis","volume":"35","author":"Saha","year":"2018","journal-title":"Sarcoidosis Vasculitis and Diffuse Lung Disease"},{"key":"10.1016\/j.mehy.2020.110005_b0320","doi-asserted-by":"crossref","unstructured":"Mahboob H, Richeson Iii R, McCain R. Zinc Chloride Smoke Inhalation Induced Severe Acute Respiratory Distress Syndrome: First Survival in the United States with Extended Duration (Five Weeks) Therapy with High Dose Corticosteroids in Combination with Lung Protective Ventilation. Case reports in critical care. 2017;2017:7952782.","DOI":"10.1155\/2017\/7952782"},{"key":"10.1016\/j.mehy.2020.110005_b0325","doi-asserted-by":"crossref","unstructured":"Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, et al. Corrigendum: Longitudinal \u201cReal-World\u201d Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece. Frontiers in medicine. 2017;4:257.","DOI":"10.3389\/fmed.2017.00213"},{"key":"10.1016\/j.mehy.2020.110005_b0330","doi-asserted-by":"crossref","unstructured":"Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respiratory research. 2011;12:143.","DOI":"10.1186\/1465-9921-12-143"},{"key":"10.1016\/j.mehy.2020.110005_b0335","doi-asserted-by":"crossref","unstructured":"Seifirad S, Haghpanah V. Inappropriate modeling of chronic and complex disorders: How to reconsider the approach in the context of predictive, preventive and personalized medicine, and translational medicine. The EPMA journal. 2019;10(3):195-209.","DOI":"10.1007\/s13167-019-00176-z"},{"key":"10.1016\/j.mehy.2020.110005_b0340","doi-asserted-by":"crossref","unstructured":"George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. The Lancet Respiratory medicine. 2020.","DOI":"10.1016\/S2213-2600(20)30225-3"},{"issue":"7","key":"10.1016\/j.mehy.2020.110005_b0345","first-page":"1481","article-title":"[Discovery of intervention effect of Chinese herbal formulas on COVID-19 pulmonary fibrosis treated by VEGFR and FGFR inhibitors]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi =","volume":"45","author":"Bian","year":"2020","journal-title":"China J Chin Mater Med"},{"key":"10.1016\/j.mehy.2020.110005_b0350","doi-asserted-by":"crossref","unstructured":"Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa GD, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? The Lancet Respiratory medicine. 2020.","DOI":"10.1016\/S2213-2600(20)30222-8"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720308380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720308380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:26:12Z","timestamp":1759692372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720308380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":70,"alternative-id":["S0306987720308380"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110005","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pirfenidone: A novel hypothetical treatment for COVID-19","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110005"}}